1 |
Jakupoglu, C., Przemeck, G. K., Schneider, M., Moreno, S. G., Mayr, N., Hatzopoulos, A. K., de Angelis, M. H., Wurst, W., Bornkamm, G. W., Brielmeier, M. and Conrad, M. 2005. Cytoplasmic thioredoxin reductase is essential for embryogenesis but dispensable for cardiac development. Mol. Cell Biol. 25, 1980-1988.
DOI
|
2 |
Loschen, G., Azzi, A., Richter, C. and Flohe, L. 1974. Superoxide radicals as precursors of mitochondrial hydrogen peroxide. FEBS Lett. 42, 68-72.
DOI
|
3 |
Lu, J., Papp, L. V., Fang, J., Rodriguez-Nieto, S., Zhivotovsky, B. and Holmgren, A. 2006. Inhibition of mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Res. 66, 4410-4418.
DOI
|
4 |
Meyer, Y., Buchanan, B. B., Vignols, F. and Reichheld, J. P. 2009. Thioredoxins and glutaredoxins: unifying elements in redox biology. Annu. Rev. Genet. 43, 335-367.
DOI
|
5 |
Liguori, I., Russo, G., Curcio, F., Bulli, G., Aran, L., DellaMorte, D., Gargiulo, G., Testa, G., Cacciatore, F., Bonaduce, D. and Abete, P. 2018. Oxidative stress, aging, and diseases. Clin. Interv. Aging 13, 757-772.
DOI
|
6 |
Powis, G., Mustacich, D. and Coon, A. 2000. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic. Biol. Med. 29, 312-322.
DOI
|
7 |
Mikkelsen, R. B. and Wardman, P. 2003. Biological chemistry of reactive oxygen and nitrogen and radiation-induced signal transduction mechanisms. Oncogene 22, 5734-5754.
DOI
|
8 |
Nordberg, J. and Arner, E. S. 2001. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic. Biol. Med. 31, 1287-1312.
DOI
|
9 |
Mahmood, D. F., Abderrazak, A., El Hadri, K., Simmet, T. and Rouis, M. 2013. The thioredoxin system as a therapeutic target in human health and disease. Antioxid. Redox Signal. 19, 1266-1303.
DOI
|
10 |
Holmgren, A. and Lu, J. 2010. Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochem. Biophys. Res. Commun. 396, 120-124.
DOI
|
11 |
Hwangbo, H., Kim, M. Y., Ji, S. Y., Kim, S. Y., Lee, H., Kim, G. Y., Park, C., Keum, Y. S., Hong, S. H., Cheong, J. and Choi, Y. H. 2020. Auranofin attenuates non-alcoholic fatty liver disease by suppressing lipid accumulation and NLRP3 inflammasome-mediated hepatic inflammation in vivo and in vitro. Antioxidants (Basel) 9, 1040.
DOI
|
12 |
Saccoccia, F., Angelucci, F., Boumis, G., Brunori, M., Miele, A. E., Williams, D. L. and Bellelli, A. 2012. On the mechanism and rate of gold incorporation into thiol-dependent flavoreductases. J. Inorg. Biochem. 108, 105-111.
DOI
|
13 |
Schafer, F. Q. and Buettner, G. R. 2001. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic. Biol. Med. 30, 1191-1212.
DOI
|
14 |
Schumacker, P. T. 2006. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 10, 175-176.
DOI
|
15 |
Soderberg, A., Sahaf, B. and Rosen, A. 2000. Thioredoxin reductase, a redox-active selenoprotein, is secreted by normal and neoplastic cells: presence in human plasma. Cancer Res. 60, 2281-2289.
|
16 |
Sonzogni-Desautels, K. and Ndao, M. 2021. Will auranofin become a golden new treatment against COVID-19? Front. Immunol. 12, 683694.
DOI
|
17 |
Arner, E. S. and Holmgren, A. 2006. The thioredoxin system in cancer. Semin. Cancer Biol. 16, 420-426.
|
18 |
Bindoli, A. and Rigobello, M. P. 2013. Principles in redox signaling: from chemistry to functional significance. Antioxid. Redox Signal. 18, 1557-1593.
DOI
|
19 |
Boonstra, J. and Post, J. A. 2004. Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene 337, 1-13.
DOI
|
20 |
Zhong, L., Arner, E. S. and Holmgren, A. 2000. Structure and mechanism of mammalian thioredoxin reductase: the active site is a redox-active selenolthiol/selenenylsulfide formed from the conserved cysteine-selenocysteine sequence. Proc. Natl. Acad. Sci. USA. 97, 5854-58549.
DOI
|
21 |
Matsui, M., Oshima, M., Oshima, H., Takaku, K., Maruyama, T., Yodoi, J. and Taketo, M. M. 1996. Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene. Dev. Biol. 178, 179-185.
DOI
|
22 |
Kim, S. J., Miyoshi, Y., Taguchi, T., Tamaki, Y., Nakamura, H., Yodoi, J., Kato, K. and Noguchi, S. 2005. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin. Cancer Res. 11, 8425-8430.
DOI
|
23 |
Rackham, O., Nichols, S. J., Leedman, P. J., Berners-Price, S. J. and Filipovska, A. 2007. A gold (I) phosphine complex selectively induces apoptosis in breast cancer cells: implications for anticancer therapeutics targeted to mitochondria. Biochem. Pharmacol. 74, 992-1002.
DOI
|
24 |
Baker, M. 2017. Deceptive curcumin offers cautionary tale for chemists. Nature 541, 144-145.
DOI
|
25 |
Das, K. C. and Das, C. K. 2000. Thioredoxin, a singlet oxygen quencher and hydroxyl radical scavenger: redox independent functions. Biochem. Biophys. Res. Commun. 277, 443-447.
DOI
|
26 |
Eriksson, S. E., Prast-Nielsen, S., Flaberg, E., Szekely, L. and Arner, E. S. 2009. High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy. Free Radic. Biol. Med. 47, 1661-1671.
DOI
|
27 |
Fang, J., Lu, J. and Holmgren, A. 2005. Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. J. Biol. Chem. 280, 25284-25290.
DOI
|
28 |
Gladyshev, V. N., Jeang, K. T. and Stadtman, T. C. 1996. Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc. Natl. Acad. Sci. USA. 93, 6146-6151.
DOI
|
29 |
Jayakumar, S., Patwardhan, R. S., Pal, D., Singh, B., Sharma, D., Kutala, V. K. and Sandur, S. K. 2017. Mitochondrial targeted curcumin exhibits anticancer effects through disruption of mitochondrial redox and modulation of TrxR2 activity. Free Radic. Biol. Med. 113, 530-538.
DOI
|
30 |
Karlenius, T. C. and Tonissen, K. F. 2010. Thioredoxin and cancer: A role for thioredoxin in all states of tumor oxygenation. Cancers (Basel) 2, 209-232.
DOI
|
31 |
Lee, S., Kim, S. M. and Lee, R. T. 2012. Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance. Antioxid. Redox Signal. 18, 1165-1207.
|
32 |
Lillig, C. H. and Holmgren, A. 2007. Thioredoxin and related molecules-from biology to health and disease. Antioxid. Redox Signal. 9, 25-47.
DOI
|
33 |
Lincoln, D. T., Ali Emadi, E. M., Tonissen, K. F. and Clarke, F. M. 2003. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res. 23, 2425-2433.
|
34 |
Madeira, J. M., Gibson, D. L., Kean, W. F. and Klegeris, A. 2012. The biological activity of auranofin: implications for novel treatment of diseases. Inflammopharmacology 20, 297-306.
DOI
|
35 |
Marzano, C., Gandin, V., Folda, A., Scutari, G., Bindoli, A. and Rigobello, M. P. 2006. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic. Biol. Med. 42, 872-881.
DOI
|
36 |
Miranda-Vizuete, A., Damdimopoulos, A. E., Pedrajas, J. R., Gustafsson, J. A. and Spyrou, G. 1999. Human mitochondrial thioredoxin reductase cDNA cloning, expression and genomic organization. Eur. J. Biochem. 261, 405-412.
DOI
|
37 |
Pessetto, Z. Y., Weir, S. J., Sethi, G., Broward, M. A. and Godwin, A. K. 2013. Drug repurposing for gastrointestinal stromal tumor. Mol. Cancer Ther. 12, 1299-1309.
DOI
|
38 |
Bu, L., Li, W., Ming, Z., Shi, J., Fang, P. and Yang, S. 2017. Inhibition of TrxR2 suppressed NSCLC cell proliferation, metabolism and induced cell apoptosis through decreasing antioxidant activity. Life Sci. 178, 35-41.
DOI
|
39 |
Cai, W., Zhang, B., Duan, D., Wu, J. and Fang, J. 2012. Curcumin targeting the thioredoxin system elevates oxidative stress in HeLa cells. Toxicol. Appl. Pharmacol. 262, 341-348.
DOI
|
40 |
Cairns, R. A., Harris, I. S. and Mak, T. W. 2011. Regulation of cancer cell metabolism. Nat. Rev. Cancer 11, 85-95.
DOI
|
41 |
Poerschke, R. L. and Moos, P. J. 2011. Thioredoxin reductase 1 knockdown enhances selenazolidine cytotoxicity in human lung cancer cells via mitochondrial dysfunction. Biochem. Pharmacol. 81, 211-221.
DOI
|
42 |
Prast-Nielsen, S., Cebula, M., Pader, I. and Arner, E. S. Noble metal targeting of thioredoxin reductase--covalent complexes with thioredoxin and thioredoxin-related protein of 14 kDa triggered by cisplatin. Free Radic. Biol. Med. 49, 1765-1778.
DOI
|
43 |
Rackham, O., Shearwood, A. M., Thyer, R., McNamara, E., Davies, S. M., Callus, B. A., Miranda-Vizuete, A., BernersPrice, S. J., Cheng, Q., Arner, E. S. and Filipovska, A. 2011. Substrate and inhibitor specificities differ between human cytosolic and mitochondrial thioredoxin reductases: Implications for development of specific inhibitors. Free Radic. Biol. Med. 50, 689-699.
DOI
|
44 |
Reddy, C. A., Somepalli, V., Golakoti, T., Kanugula, A. K., Karnewar, S., Rajendiran, K., Vasagiri, N., Prabhakar, S., Kuppusamy, P., Kotamraju, S. and Kutala, V. K. 2014. Mitochondrial-targeted curcuminoids: a strategy to enhance bioavailability and anticancer efficacy of curcumin. PLoS One 9, e89351.
DOI
|
45 |
Roder, C. and Thomson, M. J. 2015. Auranofin: repurposing an old drug for a golden new age. Drugs R. D. 15, 13-20.
DOI
|
46 |
Sabharwal, S. S. and Schumacker, P. T. 2014. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? Nat. Rev. Cancer 14, 709-721.
DOI
|
47 |
Sasada, T., Nakamura, H., Ueda, S., Sato, N., Kitaoka, Y., Gon, Y., Takabayashi A., Spyrou, G., Holmgren, A. and Yodoi, J. 1999. Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II). Free Radic. Biol. Med. 27, 504-514.
DOI
|
48 |
Shah, M. A. and Rogoff, H. A. 2021. Implications of reactive oxygen species on cancer formation and its treatment. Semin. Oncol. 48, 238-245.
|
49 |
Bhatia, M., McGrath, K. L., Di Trapani, G., Charoentong, P., Shah, F., King, M. M., Clarke, F. M. and Tonissen, K. F. 2016. The thioredoxin system in breast cancer cell invasion and migration. Redox Biol. 8, 68-78.
DOI
|
50 |
Sun, X., Wang, W., Chen, J., Cai, X., Yang, J., Yang, Y., Yan, H., Cheng, X., Ye, J., Lu, W., Hu, C., Sun, H., Pu, J. and Cao, P. 2016. The natural diterpenoid isoforretin a inhibits thioredoxin-1 and triggers potent ROS-mediated antitumor effects. Cancer Res. 77, 926-936.
|
51 |
Tamura, T. and Stadtman, T. C. 1996. A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity. Proc. Natl. Acad. Sci. USA. 93, 1006-1011.
DOI
|
52 |
Gromer, S., Urig, S. and Becker, K. 2004. The thioredoxin system-from science to clinic. Med. Res. Rev. 24, 40-89.
DOI
|
53 |
Szatrowski, T. P. and Nathan, C. F. 1991. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 51, 794-798.
|
54 |
Welsh, S. J., Bellamy, W. T., Briehl, M. M. and Powis, G. 2002. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res. 62, 5089-5095.
|
55 |
Thannickal, V. J. and Fanburg, B. L. 2000. Reactive oxygen species in cell signaling. Am. J. Physiol. Lung Cell Mol. Physiol. 279, L1005-1028.
DOI
|
56 |
Trachootham, D., Alexandre, J. and Huang, P. 2009. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov. 8, 579-591.
DOI
|
57 |
Yamada, M., Tomida, A., Yoshikawa, H., Taketani, Y. and Tsuruo, T. 1996. Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines. Clin. Cancer Res. 2, 427-432.
|
58 |
Zhang, J., Li, X., Han, X., Liu, R. and Fang, J. 2017. Targeting the thioredoxin system for cancer therapy. Trends Pharmacol. Sci. 38, 794-808.
DOI
|
59 |
Zhu, B., Ren, C., Du, K., Zhu, H., Ai, Y., Kang, F., Luo, Y., Liu, W., Wang, L., Xu, Y., Jiang, X. and Zhang, Y. 2019. Olean-28,13b-olide 2 plays a role in cisplatin-mediated apoptosis and reverses cisplatin resistance in human lung cancer through multiple signaling pathways. Biochem. Pharmacol. 170, 113642.
DOI
|
60 |
Cheng, Q., Sandalova, T., Lindqvist, Y. and Arner, E. S. 2009. Crystal structure and catalysis of the selenoprotein thioredoxin reductase 1. J. Biol. Chem. 284, 3998-4008.
DOI
|
61 |
El Feky, S. E., Ghany Megahed, M. A., Abd El Moneim, N. A., Zaher, E. R., Khamis, S. A. and Ali, L. 2021. Cytotoxic, chemosensitizing and radiosensitizing effects of curcumin based on thioredoxin system inhibition in breast cancer cells: 2D vs. 3D cell culture system. Exp. Ther. Med. 21, 506.
DOI
|
62 |
Engman, L., Al-Maharik, N., McNaughton, M., Birmingham, A. and Powis, G. 2003. Thioredoxin reductase and cancer cell growth inhibition by organotellurium antioxidants. Anticancer Drugs 14, 153-161.
DOI
|
63 |
Fritz-Wolf, K., Jortzik, E., Stumpf, M., Preuss, J., Iozef, R., Rahlfs, S. and Becker, K. 2013. Crystal structure of the Plasmodium falciparum thioredoxin reductase-thioredoxin complex. J. Mol. Biol. 425, 3446-3460.
DOI
|
64 |
Habermann, K. J., Grunewald, L., van Wijk, S. and Fulda, S. 2017. Targeting redox homeostasis in rhabdomyosarcoma cells: GSH-depleting agents enhance auranofin-induced cell death. Cell Death Dis. 8, e3067.
DOI
|
65 |
Hanschmann, E. M., Godoy, J. R., Berndt, C., Hudemann, C. and Lillig, C. H. 2013. Thioredoxins, glutaredoxins, and peroxiredoxins-molecular mechanisms and health significance: from cofactors to antioxidants to redox signaling. Antioxid. Redox Signal. 19, 1539-1605.
DOI
|
66 |
Holmgren, A. 1985. Thioredoxin. Annu. Rev. Biochem. 54, 237-271.
DOI
|
67 |
Hwangbo, H., Ji, S. Y., Kim, M. Y., Kim, S. Y., Lee, H., Kim, G. Y., Kim, S., Cheong, J. and Choi, Y. H. 2021. Anti-inflammatory effect of auranofin on palmitic acid and LPS-induced inflammatory response by modulating TLR4 and NOX4-mediated NF-κB signaling pathway in RAW264.7 macrophages. Int. J. Mol. Sci. 22, 5920.
DOI
|
68 |
Hwangbo, H., Kim, S. Y., Lee, H., Park, S. H., Hong, S. H., Park, C., Kim, G. Y., Leem, S. H., Hyun, J. W., Cheong, J. and Choi, Y. H. 2020. Auranofin enhances sulforaphane-mediated apoptosis in hepatocellular carcinoma Hep3B cells through inactivation of the PI3K/Akt signaling pathway. Biomol. Ther. (Seoul) 28, 443-455.
DOI
|
69 |
Hwang-Bo, H., Jeong, J. W., Han, M. H., Park, C., Hong, S. H., Kim, G. Y., Moon, S. K., Cheong, J., Kim, W. J., Yoo, Y. H. and Choi, Y. H. 2017. Auranofin, an inhibitor of thioredoxin reductase, induces apoptosis in hepatocellular carcinoma Hep3B cells by generation of reactive oxygen species. Gen. Physiol. Biophys. 36, 117-128.
DOI
|